Advertisement

Cephalexin Oral Suspension

[15 September 2014]

Products Affected - Description

Cephalexin oral suspension, Orchid/Karalax
125 mg/5 mL, 100 mL (NDC 42043-0142-38) - discontinued
125 mg/5 mL, 200 mL (NDC 42043-0142-58) - discontinued
250 mg/5 mL, 100 mL (NDC 42043-0143-38) - discontinued
250 mg/5 mL, 200 mL (NDC 42043-0143-58) - discontinued
 
Cephalexin oral suspension, Ranbaxy
125 mg/5 mL, 100 mL (NDC 63304-0958-01)
125 mg/5 mL, 200 mL (NDC 63304-0958-02)
250 mg/5 mL, 100 mL (NDC 63304-0959-01)
250 mg/5 mL, 200 mL (NDC 63304-0959-02)

Reason for the Shortage

  • Orchid/Karalax discontinued all cephalexin oral suspension products in the 3rd Quarter of 2013.
  • Ranbaxy has an import ban on their cephalexin oral suspension products.
  • Carlsbad Technology, Inc. discontinued all cephalexin oral suspension products in late-2012 due manufacturing cost and shortage or raw materials.
  • Teva could not provide a reason for the shortage.

Available Products

Cephalexin oral suspension, Lupin
125 mg/5 mL, 100 mL (NDC 68180-0123-01)
125 mg/5 mL, 200 mL (NDC 68180-0123-02)
250 mg/5 mL, 100 mL (NDC 68180-0124-01)
250 mg/5 mL, 200 mL (NDC 68180-0124-02)

Cephalexin oral suspension, Teva
125 mg/5 mL, 100 mL (NDC 00093-4175-73)
125 mg/5 mL, 200 mL (NDC 00093-4175-74)
250 mg/5 mL, 100 mL (NDC 00093-4177-73)
250 mg/5 mL, 200 mL (NDC 00093-4177-74)

Estimated Resupply Dates

Ranbaxy has all cephalexin oral suspension products on back order and the company cannot estimate a release date.

Related Shortages

Updated

September 15, 2014; July 9, 2014; May 14, 2014; March 12, 2014; January 8, 2014; October 21, 2013; September 25, 2013; August 27, 2013; July 19, 2013 University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement